daratumumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 5063 945721-28-8

Description:

MoleculeDescription

Synonyms:

  • daratumumab
  • HuMax-CD38
  • 3003-005
  • darzalex
Daratumumab is an IgG1k human monoclonal antibody (mAb) that binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through complement dependent cytotoxicity (CDC), antibody dependent cell mediated cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP).
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 27, 2017 PMDA Janssen Pharmaceutical KK
May 20, 2016 EMA Janssen-Cilag International N.V.
Nov. 16, 2015 FDA JANSSEN BIOTECH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infusion related reaction 654.65 18.96 481 14771 169076 50420796
Neutropenia 314.76 18.96 298 14954 147667 50442205
Neuropathy peripheral 256.97 18.96 221 15031 96536 50493336
White blood cell count decreased 210.44 18.96 215 15037 116507 50473365
Thrombocytopenia 185.82 18.96 210 15042 127463 50462409
Neutrophil count decreased 172.97 18.96 129 15123 45897 50543975
Platelet count decreased 167.91 18.96 178 15074 100548 50489324
Pneumonia 167.55 18.96 358 14894 378043 50211829
Plasma cell myeloma 160.10 18.96 106 15146 31216 50558656
Crossmatch incompatible 121.40 18.96 19 15233 20 50589852
Plasma cell myeloma recurrent 101.83 18.96 36 15216 2622 50587250
Off label use 101.43 18.96 343 14909 474083 50115789
Polyneuropathy 97.84 18.96 55 15197 12076 50577796
COVID-19 96.95 18.96 93 15159 46569 50543303
Coombs indirect test positive 96.16 18.96 16 15236 32 50589840
Tumour lysis syndrome 89.38 18.96 44 15208 7377 50582495
Disease progression 78.61 18.96 119 15133 95747 50494125
Febrile neutropenia 76.93 18.96 119 15133 97548 50492324
Cytopenia 74.07 18.96 41 15211 8734 50581138
Plasmacytoma 71.64 18.96 27 15225 2358 50587514
Body dysmorphic disorder 68.89 18.96 16 15236 249 50589623
Cytomegalovirus infection 64.42 18.96 49 15203 17913 50571959
Plasma cell leukaemia 63.92 18.96 20 15232 995 50588877
Full blood count decreased 63.14 18.96 53 15199 22293 50567579
Product use in unapproved indication 60.86 18.96 118 15134 115701 50474171
Diarrhoea 58.18 18.96 338 14914 588138 50001734
Bronchospasm 54.32 18.96 41 15211 14813 50575059
Light chain analysis increased 54.27 18.96 18 15234 1080 50588792
Septic shock 51.18 18.96 74 15178 57101 50532771
Morganella infection 47.43 18.96 14 15238 571 50589301
Atrial fibrillation 45.51 18.96 97 15155 101648 50488224
Anaemia 44.68 18.96 172 15080 252284 50337588
Constipation 44.56 18.96 140 15112 185568 50404304
Sepsis 44.41 18.96 113 15139 132812 50457060
Joint ankylosis 43.74 18.96 14 15238 750 50589122
Endocarditis bacterial 42.85 18.96 13 15239 583 50589289
Laboratory test abnormal 42.13 18.96 43 15209 23165 50566707
Meningitis listeria 40.92 18.96 12 15240 478 50589394
Pseudomyopia 40.76 18.96 8 15244 52 50589820
Drug hypersensitivity 39.89 18.96 13 15239 250997 50338875
Death 39.52 18.96 198 15054 325181 50264691
Cytomegalovirus infection reactivation 39.01 18.96 18 15234 2613 50587259
Condition aggravated 38.23 18.96 21 15231 297037 50292835
Pyrexia 37.80 18.96 219 15033 379984 50209888
Toxicity to various agents 37.48 18.96 9 15243 212490 50377382
Acute myopia 37.44 18.96 8 15244 83 50589789
Hypogammaglobulinaemia 35.83 18.96 22 15230 5677 50584195
COVID-19 pneumonia 34.81 18.96 25 15227 8370 50581502
Cerebellar haemangioma 32.81 18.96 7 15245 72 50589800
Cardiac amyloidosis 32.24 18.96 11 15241 720 50589152
Arthralgia 31.91 18.96 52 15200 438650 50151222
Plasma cells decreased 31.13 18.96 6 15246 35 50589837
Meningitis cryptococcal 30.94 18.96 12 15240 1133 50588739
Pancytopenia 30.75 18.96 74 15178 83956 50505916
Intraductal proliferative breast lesion 30.35 18.96 15 15237 2535 50587337
Leukopenia 29.74 18.96 64 15188 67464 50522408
Abdominal discomfort 28.89 18.96 17 15235 231624 50358248
Coombs direct test positive 28.55 18.96 6 15246 57 50589815
Thrombosis 28.21 18.96 56 15196 55777 50534095
Myelosuppression 28.15 18.96 27 15225 13490 50576382
Visceral leishmaniasis 28.14 18.96 9 15243 481 50589391
Headache 25.28 18.96 74 15178 506461 50083411
Respiratory tract infection 25.15 18.96 39 15213 31978 50557894
Pain 25.14 18.96 90 15162 578813 50011059
Thrombotic microangiopathy 25.13 18.96 21 15231 8770 50581102
Drug ineffective 24.02 18.96 147 15105 819186 49770686
Therapy partial responder 23.67 18.96 18 15234 6573 50583299
Swelling 23.32 18.96 16 15236 200856 50389016
Light chain analysis 23.15 18.96 4 15248 11 50589861
Endocarditis 23.01 18.96 16 15236 5091 50584781
Treatment failure 22.07 18.96 7 15245 137630 50452242
Wound 21.82 18.96 3 15249 105791 50484081
Deep vein thrombosis 21.09 18.96 59 15193 73245 50516627
Joint swelling 20.83 18.96 26 15226 245260 50344612
Urinary tract infection 20.24 18.96 126 15126 223894 50365978
Haemorrhoidal haemorrhage 20.15 18.96 13 15239 3654 50586218
Anxiety disorder 20.13 18.96 13 15239 3660 50586212
Back pain 20.03 18.96 124 15128 219906 50369966
Musculoskeletal stiffness 19.78 18.96 7 15245 128474 50461398
Bone marrow failure 19.43 18.96 32 15220 27592 50562280
Hypoperfusion 19.41 18.96 9 15243 1321 50588551
Respiratory failure 19.36 18.96 66 15186 91115 50498757
Arthropathy 19.10 18.96 12 15240 157894 50431978
Dyspnoea 19.10 18.96 250 15002 547358 50042514
Pneumonia cytomegaloviral 18.98 18.96 10 15242 1931 50587941

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infusion related reaction 1161.77 17.90 556 17601 43330 29513040
Neuropathy peripheral 185.43 17.90 223 17934 70804 29485566
White blood cell count decreased 163.18 17.90 227 17930 83135 29473235
Polyneuropathy 159.49 17.90 97 18060 12055 29544315
Pneumonia 151.92 17.90 485 17672 319687 29236683
Platelet count decreased 138.71 17.90 238 17919 104434 29451936
Neutropenia 132.55 17.90 266 17891 131445 29424925
Plasmacytoma 126.74 17.90 54 18103 3161 29553209
Plasma cell myeloma recurrent 126.07 17.90 56 18101 3627 29552743
Plasma cell myeloma 116.00 17.90 128 18029 36987 29519383
Off label use 110.49 17.90 419 17738 300381 29255989
Neutrophil count decreased 94.75 17.90 125 18032 43442 29512928
Thrombocytopenia 90.50 17.90 232 17925 134591 29421779
COVID-19 pneumonia 83.32 17.90 59 18098 9463 29546907
Respiratory tract infection 72.82 17.90 67 18090 15584 29540786
COVID-19 67.22 17.90 96 18061 35918 29520452
Disease progression 66.70 17.90 152 18005 81764 29474606
Product use in unapproved indication 63.98 17.90 155 18002 86720 29469650
Light chain analysis increased 62.36 17.90 24 18133 1077 29555293
Sepsis 61.63 17.90 210 17947 142472 29413898
Influenza 60.33 17.90 99 18058 41782 29514588
Crossmatch incompatible 57.57 17.90 9 18148 0 29556370
Coombs indirect test positive 55.64 17.90 10 18147 13 29556357
Product use issue 54.08 17.90 106 18051 51338 29505032
Chills 53.31 17.90 128 18029 71172 29485198
Plasma cell myeloma refractory 51.73 17.90 12 18145 85 29556285
Tumour lysis syndrome 47.03 17.90 50 18107 13834 29542536
Febrile neutropenia 46.49 17.90 163 17994 112077 29444293
Monoclonal immunoglobulin present 45.32 17.90 18 18139 879 29555491
Cytomegalovirus infection reactivation 44.49 17.90 27 18130 3337 29553033
Cytomegalovirus infection 40.56 17.90 60 18097 23155 29533215
Pyrexia 40.41 17.90 308 17849 287314 29269056
Progressive multifocal leukoencephalopathy 39.91 17.90 37 18120 8682 29547688
Cytopenia 39.74 17.90 39 18118 9820 29546550
Respirovirus test positive 38.41 17.90 9 18148 67 29556303
Overdose 37.68 17.90 3 18154 79816 29476554
Toxicity to various agents 37.48 17.90 31 18126 173630 29382740
Hypogammaglobulinaemia 37.03 17.90 30 18127 5877 29550493
Cerebral toxoplasmosis 34.42 17.90 17 18140 1399 29554971
Bronchospasm 33.24 17.90 35 18122 9574 29546796
Laboratory test abnormal 33.21 17.90 48 18109 18137 29538233
Hypercalcaemia 33.08 17.90 40 18117 12719 29543651
Pancytopenia 32.88 17.90 119 18038 83049 29473321
Infection 32.21 17.90 112 18045 76639 29479731
Full blood count decreased 31.85 17.90 44 18113 15948 29540422
Therapy partial responder 31.74 17.90 26 18131 5173 29551197
Cytomegalovirus viraemia 31.23 17.90 28 18129 6292 29550078
BK virus infection 27.61 17.90 23 18134 4684 29551686
JC virus infection 27.09 17.90 16 18141 1881 29554489
Pneumonia respiratory syncytial viral 26.51 17.90 12 18145 812 29555558
Autologous haematopoietic stem cell transplant 26.50 17.90 5 18152 10 29556360
Product dose omission issue 24.83 17.90 121 18036 96262 29460108
Pneumonia influenzal 23.80 17.90 13 18144 1317 29555053
Plasma cell leukaemia 23.73 17.90 11 18146 786 29555584
Back pain 23.27 17.90 124 18033 102160 29454210
Diarrhoea 23.06 17.90 308 17849 332390 29223980
Condition aggravated 22.88 17.90 34 18123 146261 29410109
Diverticular perforation 22.71 17.90 17 18140 2967 29553403
Blood immunoglobulin G decreased 22.62 17.90 12 18145 1147 29555223
Adverse drug reaction 22.25 17.90 47 18110 23973 29532397
Anaemia 22.15 17.90 204 17953 200747 29355623
Squamous cell carcinoma of skin 21.80 17.90 28 18129 9458 29546912
Septic shock 21.79 17.90 86 18071 62474 29493896
Light chain analysis decreased 21.61 17.90 5 18152 35 29556335
Blood immunoglobulin M increased 21.53 17.90 7 18150 190 29556180
Atrial fibrillation 21.32 17.90 124 18033 105522 29450848
Fatigue 20.59 17.90 290 17867 316531 29239839
Bacteraemia 20.08 17.90 36 18121 16287 29540083
Taste disorder 19.44 17.90 19 18138 4757 29551613
Mastoiditis 19.31 17.90 9 18148 651 29555719
Oxygen saturation decreased 19.20 17.90 66 18091 44871 29511499
Spinal compression fracture 18.98 17.90 21 18136 6073 29550297
Blood immunoglobulin A increased 18.72 17.90 7 18150 290 29556080
Chloroma 18.61 17.90 8 18149 478 29555892
Product preparation error 18.60 17.90 12 18145 1650 29554720
Oropharyngeal discomfort 18.21 17.90 14 18143 2542 29553828
Lower respiratory tract infection 18.10 17.90 46 18111 26456 29529914

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infusion related reaction 1237.68 16.85 792 25611 163675 64308654
Neutropenia 357.70 16.85 464 25939 239160 64233169
Pneumonia 346.46 16.85 727 25676 558849 63913480
Neuropathy peripheral 292.90 16.85 297 26106 117228 64355101
Platelet count decreased 272.40 16.85 339 26064 167372 64304957
Thrombocytopenia 263.88 16.85 387 26016 223414 64248915
Neutrophil count decreased 241.12 16.85 221 26182 76975 64395354
White blood cell count decreased 226.28 16.85 300 26103 157537 64314792
Polyneuropathy 205.84 16.85 118 26285 19776 64452553
Plasmacytoma 178.09 16.85 65 26338 3805 64468524
Off label use 177.35 16.85 614 25789 632192 63840137
Plasma cell myeloma recurrent 174.97 16.85 65 26338 4000 64468329
Plasma cell myeloma 169.91 16.85 145 26258 45930 64426399
Febrile neutropenia 152.00 16.85 274 26129 187383 64284946
COVID-19 148.33 16.85 157 26246 64983 64407346
Coombs indirect test positive 144.32 16.85 25 26378 45 64472284
Sepsis 131.97 16.85 291 26112 230050 64242279
Product use in unapproved indication 124.43 16.85 243 26160 176375 64295954
Tumour lysis syndrome 122.03 16.85 84 26319 19356 64452973
Cytomegalovirus infection 115.06 16.85 106 26297 37093 64435236
COVID-19 pneumonia 114.79 16.85 76 26327 16428 64455901
Crossmatch incompatible 113.29 16.85 19 26384 25 64472304
Cytopenia 102.20 16.85 69 26334 15402 64456927
Pyrexia 97.65 16.85 469 25934 558175 63914154
Cytomegalovirus infection reactivation 90.12 16.85 45 26358 5711 64466618
Septic shock 85.28 16.85 154 26249 105283 64367046
Pancytopenia 84.15 16.85 183 26220 143126 64329203
Respiratory tract infection 83.05 16.85 89 26314 37318 64435011
Plasma cell leukaemia 82.44 16.85 29 26374 1524 64470805
Bronchospasm 77.37 16.85 67 26336 21615 64450714
Disease progression 76.53 16.85 175 26228 141505 64330824
Anaemia 74.94 16.85 330 26073 378350 64093979
Atrial fibrillation 71.95 16.85 192 26211 170897 64301432
Light chain analysis increased 71.64 16.85 25 26378 1283 64471046
Hypogammaglobulinaemia 68.18 16.85 46 26357 10253 64462076
Arthralgia 65.75 16.85 51 26352 442209 64030120
Toxicity to various agents 64.86 16.85 34 26369 363479 64108850
Meningitis listeria 59.01 16.85 19 26384 759 64471570
Chills 56.63 16.85 153 26250 137111 64335218
Headache 56.37 16.85 81 26322 529386 63942943
Plasma cell myeloma refractory 55.07 16.85 12 26391 98 64472231
Body dysmorphic disorder 54.47 16.85 14 26389 245 64472084
Drug hypersensitivity 52.59 16.85 16 26387 237799 64234530
Therapy partial responder 52.17 16.85 39 26364 10209 64462120
Condition aggravated 50.36 16.85 47 26356 372379 64099950
Product use issue 48.12 16.85 154 26249 151561 64320768
Influenza 47.23 16.85 122 26281 106409 64365920
Overdose 45.06 16.85 6 26397 159560 64312769
Monoclonal immunoglobulin present 41.90 16.85 15 26388 830 64471499
Lymphopenia 41.71 16.85 52 26351 25605 64446724
Joint swelling 41.66 16.85 18 26385 215364 64256965
Myelosuppression 41.50 16.85 50 26353 23780 64448549
Squamous cell carcinoma of skin 40.96 16.85 36 26367 11840 64460489
Hypercalcaemia 40.77 16.85 57 26346 31359 64440970
Myelodysplastic syndrome 40.28 16.85 53 26350 27526 64444803
Pneumonia cytomegaloviral 40.27 16.85 24 26379 4315 64468014
Pneumocystis jirovecii pneumonia 38.66 16.85 52 26351 27582 64444747
Cardiac amyloidosis 37.68 16.85 16 26387 1399 64470930
Pseudomyopia 37.20 16.85 8 26395 61 64472268
Respirovirus test positive 37.03 16.85 9 26394 124 64472205
Progressive multifocal leukoencephalopathy 36.33 16.85 41 26362 18191 64454138
Deep vein thrombosis 36.32 16.85 110 26293 105072 64367257
Death 36.15 16.85 328 26075 482377 63989952
Morganella infection 35.78 16.85 14 26389 992 64471337
Cytomegalovirus viraemia 35.70 16.85 32 26371 10796 64461533
Acute myopia 34.09 16.85 8 26395 94 64472235
Abdominal discomfort 34.06 16.85 16 26387 182306 64290023
Visceral leishmaniasis 32.79 16.85 13 26390 954 64471375
Diarrhoea 32.53 16.85 444 25959 722260 63750069
Weight increased 32.41 16.85 24 26379 213324 64259005
Joint ankylosis 32.01 16.85 12 26391 757 64471572
Endocarditis bacterial 31.88 16.85 14 26389 1329 64471000
Pneumonia influenzal 31.66 16.85 17 26386 2505 64469824
Swelling 31.60 16.85 13 26390 160205 64312124
Pain 31.17 16.85 119 26284 553392 63918937
Full blood count decreased 30.84 16.85 42 26361 22540 64449789
Cerebellar haemangioma 30.68 16.85 7 26396 72 64472257
Respiratory failure 30.65 16.85 139 26264 161044 64311285
Peripheral sensory neuropathy 30.55 16.85 30 26373 11348 64460981
Plasma cells decreased 29.29 16.85 6 26397 35 64472294
Cardiac failure 28.88 16.85 119 26284 132254 64340075
Alopecia 28.77 16.85 16 26387 165674 64306655
Intraductal proliferative breast lesion 28.41 16.85 15 26388 2136 64470193
Contraindicated product administered 28.28 16.85 5 26398 107824 64364505
Injection site pain 27.47 16.85 6 26397 111402 64360927
Plasmablastic lymphoma 27.03 16.85 9 26394 400 64471929
BK virus infection 26.63 16.85 23 26380 7389 64464940
Oropharyngeal discomfort 26.48 16.85 20 26383 5315 64467014
Cytomegalovirus chorioretinitis 25.69 16.85 19 26384 4893 64467436
Bone marrow failure 25.59 16.85 59 26344 47893 64424436
Bacteraemia 25.24 16.85 42 26361 26869 64445460
Arthropathy 25.20 16.85 9 26394 120958 64351371
Infection 25.05 16.85 145 26258 184735 64287594
Oxygen saturation decreased 24.69 16.85 98 26305 107078 64365251
JC virus infection 24.66 16.85 16 26387 3339 64468990
Leukopenia 24.48 16.85 94 26309 101148 64371181
Haematotoxicity 24.01 16.85 28 26375 12868 64459461
Somnolence 23.80 16.85 29 26374 203616 64268713
Depression 23.72 16.85 24 26379 183267 64289062
Back pain 23.48 16.85 179 26224 249992 64222337
Therapeutic product effect decreased 23.33 16.85 9 26394 115342 64356987
Blister 22.96 16.85 3 26400 80964 64391365
Minimal residual disease 22.95 16.85 8 26395 409 64471920
Pathological fracture 22.80 16.85 23 26380 8982 64463347
Mobility decreased 22.47 16.85 4 26399 85836 64386493
Atrial flutter 21.99 16.85 33 26370 19347 64452982
Pneumonia respiratory syncytial viral 21.85 16.85 11 26392 1420 64470909
Hepatitis E 21.41 16.85 13 26390 2418 64469911
Blood immunoglobulin A increased 20.80 16.85 8 26395 541 64471788
Anxiety 20.52 16.85 32 26371 202617 64269712
Diverticular perforation 20.42 16.85 17 26386 5196 64467133
Neutropenic sepsis 20.08 16.85 35 26368 23237 64449092
Pulmonary embolism 19.96 16.85 115 26288 146241 64326088
Pneumococcal sepsis 19.84 16.85 10 26393 1294 64471035
Parainfluenzae virus infection 19.69 16.85 16 26387 4727 64467602
Coombs test positive 19.62 16.85 6 26397 202 64472127
Psoriasis 19.52 16.85 3 26400 71700 64400629
Treatment failure 19.25 16.85 12 26391 116804 64355525
Abdominal sepsis 19.19 16.85 11 26392 1839 64470490
Atypical haemolytic uraemic syndrome 19.01 16.85 8 26395 684 64471645
Mastoiditis 18.87 16.85 10 26393 1435 64470894
Meningitis cryptococcal 18.87 16.85 13 26390 2996 64469333
Cytokine release syndrome 18.86 16.85 32 26371 20797 64451532
Blood immunoglobulin M increased 18.62 16.85 7 26396 445 64471884
Gait disturbance 18.59 16.85 26 26377 172129 64300200
Drug ineffective 18.53 16.85 238 26165 840009 63632320
Musculoskeletal stiffness 18.52 16.85 14 26389 123192 64349137
Taste disorder 18.43 16.85 21 26382 9412 64462917
Product preparation error 17.67 16.85 14 26389 3991 64468338
Intentional product misuse 17.60 16.85 4 26399 72291 64400038
Urinary tract infection 17.58 16.85 158 26245 231438 64240891
Abdominal pain upper 17.38 16.85 28 26375 175002 64297327
Polyomavirus-associated nephropathy 17.22 16.85 15 26388 4873 64467456
Hepatitis B reactivation 17.22 16.85 15 26388 4874 64467455
Wound 17.15 16.85 5 26398 76472 64395857
Spinal cord compression 17.13 16.85 16 26387 5687 64466642
H1N1 influenza 17.13 16.85 11 26392 2255 64470074
Colorectal adenocarcinoma 17.06 16.85 6 26397 315 64472014

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FC01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
CD38 (Clusters of Differentiation 38) inhibitors
FDA CS M0001357 Antibodies, Monoclonal
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000192335 CD38-directed Antibody Interactions
FDA EPC N0000192336 CD38-directed Cytolytic Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Systemic AL amyloidosis indication 23132008
Multiple myeloma indication 109989006 DOID:9538




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Lymphocyte differentiation antigen CD38 Tumour-associated antigen ANTIBODY BINDING Kd 8.22 IUPHAR DRUG LABEL

External reference:

IDSource
D10777 KEGG_DRUG
4035125 VANDF
CHEMBL1743007 ChEMBL_ID
C556306 MESH_SUPPLEMENTAL_RECORD_UI
7395 IUPHAR_LIGAND_ID
9128 INN_ID
DB09331 DRUGBANK_ID
4Z63YK6E0E UNII
1721947 RXNORM
237137 MMSL
31294 MMSL
d08399 MMSL
716016006 SNOMEDCT_US
781328004 SNOMEDCT_US
C2346801 UMLSCUI
016591 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
DARZALEX HUMAN PRESCRIPTION DRUG LABEL 1 57894-502 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAVENOUS BLA 32 sections
DARZALEX HUMAN PRESCRIPTION DRUG LABEL 1 57894-502 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAVENOUS BLA 32 sections
Darzalex Faspro HUMAN PRESCRIPTION DRUG LABEL 2 57894-503 INJECTION 1800 mg SUBCUTANEOUS BLA 32 sections
Darzalex Faspro HUMAN PRESCRIPTION DRUG LABEL 2 57894-503 INJECTION 1800 mg SUBCUTANEOUS BLA 32 sections
Darzalex IV HUMAN PRESCRIPTION DRUG LABEL 1 57894-505 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAVENOUS BLA 32 sections
Darzalex IV HUMAN PRESCRIPTION DRUG LABEL 1 57894-505 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAVENOUS BLA 32 sections